SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SANA

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/09	05:49	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SANA	Sana Biotechnology Inc
2024/05/09	05:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
2024/05/09	05:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/05/09	05:05	GlobeNewswire Inc.	Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
2024/05/07	05:05	GlobeNewswire Inc.	Sana Biotechnology to Present at May and June 2024 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
2024/03/09	06:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/03/09	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/03/01	06:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/03/01	06:05	GlobeNewswire Inc.	Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/29	06:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/15	06:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/14	06:05	GlobeNewswire Inc.	Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/13	06:05	GlobeNewswire Inc.	Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/09	07:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/09	06:49	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/08	15:22	GlobeNewswire Inc.	Sana Biotechnology Announces Pricing of Upsized Public Offering	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/08	11:59	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/08	07:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/08	06:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/02/08	06:01	GlobeNewswire Inc.	Sana Biotechnology Announces Proposed Public Offering of Common Stock	NASDAQ:SANA	Sana Biotechnology Inc
2024/01/09	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/01/05	23:00	GlobeNewswire Inc.	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies	NASDAQ:SANA	Sana Biotechnology Inc
2024/01/04	06:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:SANA	Sana Biotechnology Inc
2023/12/19	06:51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
2023/12/16	06:34	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2023/12/12	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2023/12/11	23:00	GlobeNewswire Inc.	Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
2023/12/02	06:05	GlobeNewswire Inc.	Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System	NASDAQ:SANA	Sana Biotechnology Inc
2023/11/28	09:01	PR Newswire (US)	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders	NASDAQ:SANA	Sana Biotechnology Inc
2023/11/21	23:00	GlobeNewswire Inc.	Sana Biotechnology to Present at November and December 2023 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc